[go: up one dir, main page]

MX2024013464A - Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos - Google Patents

Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos

Info

Publication number
MX2024013464A
MX2024013464A MX2024013464A MX2024013464A MX2024013464A MX 2024013464 A MX2024013464 A MX 2024013464A MX 2024013464 A MX2024013464 A MX 2024013464A MX 2024013464 A MX2024013464 A MX 2024013464A MX 2024013464 A MX2024013464 A MX 2024013464A
Authority
MX
Mexico
Prior art keywords
tlr7
antagonists
compounds
useful
formula
Prior art date
Application number
MX2024013464A
Other languages
English (en)
Inventor
Brian Sherer
Ruoxi Lan
Nadia Brugger
Xiaoling Chen
Momar Toure
Esther Cleary
Lizbeth Celeste Deselm
Yanping Wang
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2024013464A publication Critical patent/MX2024013464A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se relaciona con compuestos de la Fórmula (I) y composiciones farmacéuticamente aceptables de los mismos, útiles como antagonistas de TLR7/8.
MX2024013464A 2018-07-31 2021-01-06 Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos MX2024013464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712439P 2018-07-31 2018-07-31
PCT/EP2019/070312 WO2020025517A1 (en) 2018-07-31 2019-07-29 Tlr7/8 antagonists and uses thereof

Publications (1)

Publication Number Publication Date
MX2024013464A true MX2024013464A (es) 2024-12-06

Family

ID=67660056

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021000093A MX2021000093A (es) 2018-07-31 2019-07-29 Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2024013464A MX2024013464A (es) 2018-07-31 2021-01-06 Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021000093A MX2021000093A (es) 2018-07-31 2019-07-29 Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.

Country Status (13)

Country Link
US (1) US20210300940A1 (es)
EP (1) EP3830080A1 (es)
JP (2) JP7491900B2 (es)
KR (1) KR20210040085A (es)
CN (1) CN112513024A (es)
AU (2) AU2019313441B2 (es)
BR (2) BR112021001618A2 (es)
CA (1) CA3108099A1 (es)
IL (1) IL280479A (es)
MX (2) MX2021000093A (es)
SG (1) SG11202100818RA (es)
TW (3) TWI827641B (es)
WO (1) WO2020025517A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3889145T1 (sl) 2015-12-17 2024-05-31 Merck Patent Gmbh 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj
SG11201900947RA (en) 2016-08-08 2019-02-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
WO2019125849A1 (en) * 2017-12-19 2019-06-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
EP3950059A4 (en) * 2019-03-29 2023-01-11 Nippon Chemiphar Co., Ltd. USE OF A T-TYPE CALCIUM CHANNEL BLOCKER TO TREAT PRURITUS
JP2022547729A (ja) * 2019-09-16 2022-11-15 エフ．ホフマン－ラ ロシュ アーゲー 自己免疫疾患を治療するためのピペリジニルアミン化合物
MX2022006466A (es) 2019-11-28 2022-08-17 Bayer Ag Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activacion inmune.
EP4149463A1 (en) * 2020-05-14 2023-03-22 Merck Healthcare KGaA Tlr7/8 antagonists for the treatment of coronavirus infections
US20240101549A1 (en) 2020-12-17 2024-03-28 Astrazeneca Ab N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides
US11661431B2 (en) 2021-04-16 2023-05-30 Gilead Sciences, Inc. Thienopyrrole compounds
TWI849499B (zh) 2021-09-10 2024-07-21 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2024153063A1 (zh) * 2023-01-18 2024-07-25 苏州科睿思制药有限公司 Enpatoran的晶型及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物
KR102365952B1 (ko) * 2013-10-14 2022-02-22 에자이 알앤드디 매니지먼트 가부시키가이샤 선택적으로 치환된 퀴놀린 화합물
CN104557913B (zh) * 2013-10-28 2017-02-08 上海汇伦生命科技有限公司 吡啶并嘧啶类化合物，其制备方法和用途
PE20160692A1 (es) 2013-11-12 2016-07-28 Hoffmann La Roche Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos
EP3317265A4 (en) 2015-07-01 2019-04-17 Northwestern University SUBSTITUTED CHINAZOLIN COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
SI3889145T1 (sl) * 2015-12-17 2024-05-31 Merck Patent Gmbh 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj
CN106632089B (zh) * 2016-11-04 2019-06-18 中山大学 一类喹唑啉类化合物及其制备方法与应用
EP4248968A3 (en) 2017-07-18 2023-12-06 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
CN111801015B (zh) * 2017-12-12 2022-03-18 先正达参股股份有限公司 植物生长调节
WO2019125849A1 (en) 2017-12-19 2019-06-27 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof

Also Published As

Publication number Publication date
CN112513024A (zh) 2021-03-16
BR122023023308A2 (pt) 2024-02-20
KR20210040085A (ko) 2021-04-12
EP3830080A1 (en) 2021-06-09
AU2019313441A1 (en) 2021-03-18
TWI827641B (zh) 2024-01-01
TW202423913A (zh) 2024-06-16
BR112021001618A2 (pt) 2021-04-27
TW202019899A (zh) 2020-06-01
CA3108099A1 (en) 2020-02-06
JP7491900B2 (ja) 2024-05-28
AU2019313441B2 (en) 2024-05-23
TWI880472B (zh) 2025-04-11
US20210300940A1 (en) 2021-09-30
SG11202100818RA (en) 2021-02-25
AU2024203629A1 (en) 2024-06-20
JP2024105611A (ja) 2024-08-06
MX2021000093A (es) 2021-03-25
IL280479A (en) 2021-03-01
WO2020025517A1 (en) 2020-02-06
TW202542153A (zh) 2025-11-01
JP2021533125A (ja) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2024013464A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
ZA202005326B (en) Heteroaryl compounds as type ii irak inhibitors and uses hereof
MY210123A (en) Tlr7/8 antagonists and uses thereof
MX2019001096A (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
EP4252848A3 (en) Oxysterols and methods of use thereof
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
TN2018000424A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
EP4609866A3 (en) Oxysterols and methods of use thereof
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MY209603A (en) Hydroxypyridoxazepines as nrf2 activators
MY192425A (en) Polymorphs
TN2017000031A1 (en) Imidazopyridazine compounds
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2021003427A (es) Nuevos oxadiazoles.
MX379859B (es) Compuestos de indolinona y su uso en el tratamiento de enfermedades fibróticas.
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin